Form 8-K - Current report:
SEC Accession No. 0001193125-25-198747
Filing Date
2025-09-09
Accepted
2025-09-09 06:09:59
Documents
15
Period of Report
2025-09-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d80074d8k.htm   iXBRL 8-K 58955
2 EX-2.1 d80074dex21.htm EX-2.1 567309
3 EX-99.1 d80074dex991.htm EX-99.1 18626
7 GRAPHIC g80074dsp004.jpg GRAPHIC 8016
  Complete submission text file 0001193125-25-198747.txt   933800

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA trml-20250908.xsd EX-101.SCH 2865
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE trml-20250908_lab.xml EX-101.LAB 18734
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trml-20250908_pre.xml EX-101.PRE 11716
17 EXTRACTED XBRL INSTANCE DOCUMENT d80074d8k_htm.xml XML 3765
Mailing Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010
Business Address 27 WEST 24TH STREET SUITE 702 NEW YORK NY 10010 646-481-9832
Tourmaline Bio, Inc. (Filer) CIK: 0001827506 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40384 | Film No.: 251301599
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)